Jeffrey K. Weber

Seung-gu Kang, Jeffrey K. Weber, Joseph A. Morrone et al.

Proteins in complex with small molecule ligands represent the core of structure-based drug discovery. However, three-dimensional representations are absent from most deep-learning-based generative models. We here present a graph-based generative modeling technology that encodes explicit 3D protein-ligand contacts within a relational graph architecture. The models combine a conditional variational autoencoder that allows for activity-specific molecule generation with putative contact generation that provides predictions of molecular interactions within the target binding pocket. We show that molecules generated with our 3D procedure are more compatible with the binding pocket of the dopamine D2 receptor than those produced by a comparable ligand-based 2D generative method, as measured by docking scores, expected stereochemistry, and recoverability in commercial chemical databases. Predicted protein-ligand contacts were found among highest-ranked docking poses with a high recovery rate. This work shows how the structural context of a protein target can be used to enhance molecule generation.

Yoel Shoshan, Moshiko Raboh, Michal Ozery-Flato et al.

Large language models applied to vast biological datasets have the potential to transform biology by uncovering disease mechanisms and accelerating drug development. However, current models are often siloed, trained separately on small-molecules, proteins, or transcriptomic data, limiting their ability to capture complex, multi-modal interactions. Effective drug discovery requires computational tools that integrate multiple biological entities while supporting prediction and generation, a challenge existing models struggle to address. For this purpose, we present MAMMAL - Molecular Aligned Multi-Modal Architecture and Language - a versatile method applied to create a multi-task foundation model that learns from large-scale biological datasets across diverse modalities, including proteins, small-molecules, and omics. MAMMAL's structured prompt syntax supports classification, regression, and generation tasks while handling token and scalar inputs and outputs. Evaluated on eleven diverse downstream tasks, it reaches a new state of the art (SOTA) in nine tasks and is comparable to SOTA in two tasks, all within a unified architecture, unlike prior task-specific models. Additionally, we explored Alphafold 3 binding prediction capabilities on antibody-antigen and nanobody-antigen complexes showing significantly better classification performance of MAMMAL in 3 out of 4 targets. The model code and pretrained weights are publicly available at https://github.com/BiomedSciAI/biomed-multi-alignment and https://huggingface.co/ibm/biomed.omics.bl.sm.ma-ted-458m

Ella Barkan, Ibrahim Siddiqui, Kevin J. Cheng et al.

Monoclonal antibodies (mAbs) represent one of the most prevalent FDA-approved modalities for treating autoimmune diseases, infectious diseases, and cancers. However, discovery and development of therapeutic antibodies remains a time-consuming and expensive process. Recent advancements in machine learning (ML) and artificial intelligence (AI) have shown significant promise in revolutionizing antibody discovery and optimization. In particular, models that predict antibody biological activity enable in-silico evaluation of binding and functional properties; such models can prioritize antibodies with the highest likelihoods of success in costly and time-intensive laboratory testing procedures. We here explore an AI model for predicting the binding and receptor blocking activity of antibodies against influenza A hemagglutinin (HA) antigens. Our present model is developed with the MAMMAL framework for biologics discovery to predict antibody-antigen interactions using only sequence information. To evaluate the model's performance, we tested it under various data split conditions to mimic real-world scenarios. Our models achieved an AUROC $\geq$ 0.91 for predicting the activity of existing antibodies against seen HAs and an AUROC of 0.9 for unseen HAs. For novel antibody activity prediction, the AUROC was 0.73, which further declined to 0.63-0.66 under stringent constraints on similarity to existing antibodies. These results demonstrate the potential of AI foundation models to transform antibody design by reducing dependence on extensive laboratory testing and enabling more efficient prioritization of antibody candidates. Moreover, our findings emphasize the critical importance of diverse and comprehensive antibody datasets to improve the generalization of prediction models, particularly for novel antibody development.

Seung-gu Kang, Joseph A. Morrone, Jeffrey K. Weber et al.

The application of deep learning to generative molecule design has shown early promise for accelerating lead series development. However, questions remain concerning how factors like training, dataset, and seed bias impact the technology's utility to medicine and computational chemists. In this work, we analyze the impact of seed and training bias on the output of an activity-conditioned graph-based variational autoencoder (VAE). Leveraging a massive, labeled dataset corresponding to the dopamine D2 receptor, our graph-based generative model is shown to excel in producing desired conditioned activities and favorable unconditioned physical properties in generated molecules. We implement an activity swapping method that allows for the activation, deactivation, or retention of activity of molecular seeds, and we apply independent deep learning classifiers to verify the generative results. Overall, we uncover relationships between noise, molecular seeds, and training set selection across a range of latent-space sampling procedures, providing important insights for practical AI-driven molecule generation.

Joseph A. Morrone, Jeffrey K. Weber, Tien Huynh et al.

We present a simple, modular graph-based convolutional neural network that takes structural information from protein-ligand complexes as input to generate models for activity and binding mode prediction. Complex structures are generated by a standard docking procedure and fed into a dual-graph architecture that includes separate sub-networks for the ligand bonded topology and the ligand-protein contact map. This network division allows contributions from ligand identity to be distinguished from effects of protein-ligand interactions on classification. We show, in agreement with recent literature, that dataset bias drives many of the promising results on virtual screening that have previously been reported. However, we also show that our neural network is capable of learning from protein structural information when, as in the case of binding mode prediction, an unbiased dataset is constructed. We develop a deep learning model for binding mode prediction that uses docking ranking as input in combination with docking structures. This strategy mirrors past consensus models and outperforms the baseline docking program in a variety of tests, including on cross-docking datasets that mimic real-world docking use cases. Furthermore, the magnitudes of network predictions serve as reliable measures of model confidence